GALLIUM: The Largest Trial in Previously Untreated Follicular Lymphoma (FL) 1

This Phase III, open-label, randomized trial was designed to answer one primary question: In patients with previously untreated FL, did the GAZYVA (obinutuzumab) based regimen deliver superior PFS compared with the rituximab product-based regimen? 1

The GALLIUM trial studied patients with previously untreated follicular lymphoma (Grades 1-3a, stage III/IV or stage II bulky disease [≥7 cm])

  • Primary endpoint: PFS as assessed by Independent Review Committee (IRC)
  • Additional endpoint: Response rates at end of induction (IRC-assessed, assessed by CT)

GAZYVA WAS STUDIED IN A TRIAL OF OVER 1,200 PATIENTS WITH PREVIOUSLY UNTREATED FL 1

With chemotherapy* for stage II bulky, III, and IV patients

GALLIUM evaluated GAZYVA vs rituximab product when each was combined with bendamustine, CHOP, or CVP and followed by GAZYVA or rituximab product monotherapy, respectively

The GAZYVA and rituximab product arms were generally well balanced with respect to demographic factors and baseline disease characteristics6